drugset / Trial / NCT00610506

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

NCT00610506

Phase 3 Completed 15 enrolled Duke University Forest Laboratories · collab
NaSingle-groupSingle-blindTreatment

Summary

Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed as an open-label study to gather pilot data to examine whether escitalopram has clinical utility in the treatment of major depression with atypical features. Because of the exploratory nature of the design, no specific study hypotheses can be generated regarding efficacy of the drug. Our primary hypothesis is that the effect size of escitalopram in atypical depression will be similar to the effect size of escitalopram in major depression, its FDA approved indication.

Timeline

Start
2005-10
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 20 mg